Showing 1971-1980 of 3223 results for "".
- Allergan Adds Two Experts to Eye Care Divisionhttps://modernod.com/news/allergan-adds-two-experts-to-eye-care-division/2479311/Allergan has announced two new additions to leadership roles in Allergan Eye Care. E. Randy Craven, MD, FACS, has joined Allergan Eye Care as medical director of the U.S. medical affairs glaucoma organization. A pioneer of minimally-invasive glaucoma surgery, Dr. Craven previously served a
- Alcon’s ORA System Reaches 2 Million Caseshttps://modernod.com/news/alcons-ora-system-reaches-2-million-cases/2479303/Alcon announced its Optiwave Refractive Analysis (ORA) intraoperative aberrometer system has reached 2 million cases worldwide. This milestone signifies an important leap forward in cataract surgery by delivering greater accuracy than preoperative calculation methods alone. The ORA Syste
- Alcon Data Highlights Benefits of Specific AcrySof Modelshttps://modernod.com/news/alcon-data-highlights-benefits-of-specific-acrysof-models/2479232/Alcon has announced the publication of the National Ophthalmology Database (NOD) audit by The Royal College of Ophthalmologists (RCOphth), which collects data on cataract surgery performed in England, Wales and Guerns
- Alimera Sciences Appoints David Dyer, MD, as Chief Retina Specialisthttps://modernod.com/news/alimera-sciences-appoints-david-dyer-md-as-chief-retina-specialist/2479222/Alimera Sciences has announced the expansion of its leadership team with the appointment of David Dyer, MD, as chief retina specialist, effective today. Dr. Dyer brings his extensive medical knowledge and business exp
- Shamir and Alpine F1 Team Form Partnershiphttps://modernod.com/news/shamir-and-alpine-f1-team-form-partnership/2479181/Shamir Optical Industry and Alpine F1 Team have announced an innovative new partnership that will see Shamir become Alpine F1 Team’s optical performance partner. This collaboration, initiated by
- New Partnership Expands Alcon’s In-Office Dry Eye and Ocular Health Portfoliohttps://modernod.com/news/new-partnership-expands-alcons-in-office-dry-eye-and-ocular-health-portfolio/2479180/Alcon has gained exclusive rights to sell the technology and accompanying products of BlephEx, a provider of bacterial biofilm theory, in the United States effective May 1, 2021. Terms of the deal were not disclosed. The BlephEx eyelid cleaning device and LashCam iR WIFI
- Pfizer, BioNTech Seek EU Nod to Allow COVID-19 Vaccine Use in Younger Teenshttps://modernod.com/news/pfizer-biontech-seek-eu-nod-to-allow-covid-19-vaccine-use-in-younger-teens/2479158/Pfizer and BioNTech said they have asked the European Medicines Agency (EMA) to extend the conditional marketing authorization for their COVID-19 vaccine Comirnaty to adolescents 12 to 15 years of age. The companies recently made a similar request to the FDA for the vaccine, which is already auth
- New Alcon Data on Contact Lens, Dry Eye, and Ocular Health to Be Presented at ARVO 2021https://modernod.com/news/new-alcon-data-on-contact-lens-dry-eye-and-ocular-health-to-be-presented-at-arvo-2021/2479151/Alcon will present new data on several of its latest contact lens, dry eye, and ocular health innovations during the Association for Research in Vision and Ophthalmology (ARVO) 2021 virtual meeting taking place May 1-7. Alcon boasts a robust scientific showing at the meeting with nine accepted ab
- Alcon Presents Highlights of ARVO 2021 Datahttps://modernod.com/news/alcon-presents-highlights-of-arvo-2021-data/2479149/Alcon will be presenting new data at the Association for Research in Vision and Ophthalmology (ARVO) Virtual Meeting (May 1-7). Presentations include data for the Systane iLux MGD Thermal Pulsation System, Precision1 daily disposable contact lenses, and a forthcoming reusable monthly contact lens
- Alcon to Acquire US Commercialization Rights to Glaucoma Eye Drop Simbrinzahttps://modernod.com/news/alcon-to-acquire-us-commercialization-rights-to-ophthalmic-eye-drop-simbrinza/2479138/Alcon announced it has signed an agreement to acquire exclusive U.S. commercialization rights to Simbrinza (brinzolamide/brimonidine tartrate ophthalmic suspension) 1%/0.2% from Novartis. Under terms of the deal, Alcon will pay $355 million at closing, which is expected to occur in the sec